Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Aishwarya Vijay, Clyde W Yancy
The treatment of heart failure (HF) with reduced ejection fraction (HFrEF) has substantially developed over the past decades. More than ever before, the application of appropriate evidence-based medical therapy for HFrEF is associated with remarkable improvements in survival, noteworthy increases in quality of life, and a marked reduction in symptomatic HF sufficient to warrant hospitalization. These enhanced clinical outcomes are driven by the "four pillars" of HF therapy: 1) evidence-based beta blockers, 2) Renin-angiotensin-aldosterone system inhibitors (angiotensin-converting enzyme inhibitors /angiotensin II receptor blockers or angiotensin receptor-neprilysin inhibitors, 3) mineralocorticoid receptor antagonists, and most recently, 4) sodium-glucose cotransporter-2 inhibitors...
January 10, 2024: Progress in Cardiovascular Diseases
#22
JOURNAL ARTICLE
Aliya Daulat, Jenny MacGillivray, Margaret Sidsworth, Ricky D Turgeon
BACKGROUND: Tachycardia-mediated cardiomyopathy (TMC) is a reversible form of heart failure with reduced ejection fraction (HFrEF), most commonly caused by atrial fibrillation or atrial flutter. Evidence for its management is scarce, and practice patterns are highly variable. OBJECTIVE: To describe management patterns for HFrEF and atrial arrhythmias in patients with TMC at a specialty heart failure clinic. METHODS: This retrospective cohort study involved adults with HFrEF and a physician-determined diagnosis of TMC, with an initial visit for this problem between October 2018 and October 2019...
2024: Canadian Journal of Hospital Pharmacy
#23
JOURNAL ARTICLE
Tasnim Mohaissen, Agnieszka Kij, Anna Bar, Brygida Marczyk, Kamila Wojnar-Lason, Elżbieta Buczek, Agnieszka Karas, Ana B Garcia-Redondo, Ana M Briones, Stefan Chlopicki
The angiotensin (Ang)-(1-12)/II pathway contributes to cardiac pathology. However, its involvement in the development of peripheral endothelial dysfunction associated with heart failure (HF) remains unknown. Therefore, this study aimed to characterise the effect of exogenous Ang-(1-12) and its conversion to Ang II on endothelial function using the murine model of HF (Tgαq*44 mice), focusing on the role of chymase and vascular-derived thromboxane A2 (TXA2 ). Ex vivo myographic assessments of isolated aorta showed impaired endothelium-dependent vasodilation in late-stage HF in 12-month-old Tgαq*44 mice...
December 27, 2023: European Journal of Pharmacology
#24
MULTICENTER STUDY
Wanwarang Wongcharoen, Nichanan Osataphan, Siriluck Gunaparn, Suphot Srimahachota, Pornwalee Porapakkham, Somchai Dutsadeevettakul, Arintaya Phrommintikul
The advantage of angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) in patients with preserved LV systolic function is uncertain. We aimed to investigate the effects of ACEI/ARB in high atherosclerotic risk patients without overt heart failure (HF) on long-term major cardiovascular outcomes (MACEs). The Cohort Of patients with high Risk for cardiovascular Events (CORE-Thailand) registry is a prospective, multicenter, observational, longitudinal study of Thai patients with high atherosclerotic risk...
December 27, 2023: Scientific Reports
#25
JOURNAL ARTICLE
Yue Wu, Nannan Huang, Tienan Sun, Biyang Zhang, Shiyu Zhang, Pengyu Zhang, Chunxia Zhang
BACKGROUND: Lactate was a prognostic indicator for acute myocardial infarction (AMI) patients. However, the association between normalized lactate load, representing hypoxic burden over time, and in-hospital mortality remained uncertain. METHODS: The data for this study was obtained from the Medical Information Mart for Intensive Care IV (MIMIC-IV, version 2.1) database. The normalized lactate load, describing the average intensity of hyperlactatemia, was calculated as the area under the curve (AUC) of lactate divided by time...
March 15, 2024: International Journal of Cardiology
#26
JOURNAL ARTICLE
Dora B Balogh, Agnes Molnar, Arianna Degi, Akos Toth, Lilla Lenart, Adar Saeed, Adrienn Barczi, Attila J Szabo, Laszlo J Wagner, Gyorgy Reusz, Andrea Fekete
Diabetic cardiovascular complications are associated with up to 50% mortality, and current therapies are not effective enough. Renin-angiotensin-aldosterone system inhibitors (RAASis) are the standard of care for diabetic patients with hypertension and albuminuria. Based on our previous studies reporting the renoprotective effects of low-dose RAASis, here, we hypothesized that low-dose RAASi treatment has cardioprotective and antifibrotic benefits in type 1 diabetes mellitus (T1DM). After five weeks of T1DM, adult male Wistar rats received low doses of ramipril, losartan, or eplerenone for two weeks...
December 1, 2023: International Journal of Molecular Sciences
#27
REVIEW
Keisuke Narita, Satoshi Hoshide, Kazuomi Kario
Although various guidelines for cardiovascular disease prevention have been established, the optimal drug therapy is often not implemented due to poor medication adherence and the clinical inertia of healthcare practitioners. Polypill strategies are one solution to this problem. Previous studies have established the usefulness of polypills, i.e., combination tablets including three or more medications, for the prevention of cardiovascular disease. For this purpose, the polypills generally contain an antiplatelet medication, an antihypertensive medication, and a statin...
November 22, 2023: Journal of Clinical Medicine
#28
JOURNAL ARTICLE
Fabio Papa Taniguchi, Sabrina Bernardez-Pereira, Antônio Luiz Pinho Ribeiro, Louise Morgan, Anne B Curtis, Kathryn Taubert, Denilson Campos de Albuquerque, Sidney C Smith, Angêlo Amato Vincenzo de Paola
BACKGROUND: A Nationwide Initiative to Improve Cardiology Quality: The Best Practice in Cardiology Program in Brazil ACEI/ARB: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; LVEF: left ventricular ejection fraction; LVSD: left ventricular systolic dysfunction; AF: atrial fibrillation; PT/INR: prothrombin time/international normalized ratio. BACKGROUND: Despite significant progress in improving the quality of cardiovascular care, persistent gaps remain in terms of inconsistent adherence to guideline recommendations...
November 2023: Arquivos Brasileiros de Cardiologia
#29
REVIEW
Johao Escobar, Anurag Rawat, Fabricio Maradiaga, Abraham K Isaak, Sana Zainab, Mohammedsefa Arusi Dari, Martha Mekonen Gdey, Areeba Khan
Patients with acute myocardial infarction (AMI) are usually treated with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB). The aim of this meta-analysis is to compare outcomes between ACEi and ARB in patients with myocardial infarction (MI). This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Three major online databases, including PubMed, EMBASE, and the Cochrane Library, were thoroughly searched to find studies comparing ACEi and ARB in patients with MI from January 1, 2000, onwards, without language or publication restrictions...
October 2023: Curēus
#30
JOURNAL ARTICLE
Juan Esteban Gómez-Mesa, Juliana María Gutiérrez-Posso, Manuela Escalante-Forero, Brayan Daniel Córdoba-Melo, Paula Andrea Cárdenas-Marín, Eduardo R Perna, Mádelyn Raquel Valle-Ramos, Germán Camilo Giraldo-González, Noel Alberto Flórez-Alarcón, Ida Fabiola Rodríguez-Caballero, Cristian Núñez-Carrizo, Luz Teresa Cabral-Gueyraud, Sarah Raquel Marte-Arias, Elizabeth Ashley Hardin, Amada Álvarez-Sangabriel, María Eugenia Menjívar-De Ramos, Kwame van der Hilst, Licurgo Jacob Cruz-Díaz, Sergio Roberto Fausto Ovando, Luis Arturo Rodríguez, Juan Pablo Escalante, Gabriela Ormaechea-Gorricho, Norberto Raul Bornancini, María Juliana Rodríguez-González, Sebastián Campbell-Quintero, Raquel E González-Hormostay, Guillermo Oviedo-Pereira, Guillermo Trout-Guardiola, Juan Justiniano Encina, Ana Margarita Jerez-Castro, Mark Drazner, Daniel Quesada-Chaves, Alexander Romero-Guerra, Víctor Alejandro Rossel-Mariángel, Mario Speranza
BACKGROUND: About 80% of cardiovascular diseases (including heart failure [HF]) occur in low-income and developing countries. However, most clinical trials are conducted in developed countries. HYPOTHESIS: The American Registry of Ambulatory or Acutely Decompensated Heart Failure (AMERICCAASS) aims to describe the sociodemographic characteristics of HF, comorbidities, clinical presentation, and pharmacological management of patients with ambulatory or acutely decompensated HF in America...
November 30, 2023: Clinical Cardiology
#31
JOURNAL ARTICLE
Qing Ji
BACKGROUND: Sacubitril-valsartan, an inhibitor of the angiotensin receptor neprilysin (ARNi), has been purported to exhibit superiority over angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in individuals diagnosed with heart failure. HYPOTHESIS: This paper gives an updated meta-analysis comparing the efficacy and safety of sacubitril-valsartan to that of standard treatment for different types of heart failure. RESULTS: The meta-analysis comprised a total of nine randomized controlled trials (RCTs), incorporating data from a substantial sample size of 15 939 patients...
November 27, 2023: Clinical Cardiology
#32
REVIEW
Mohamed Abuelazm, Amr Badr, Mustafa Turkmani, Mostafa Atef Amin, Ahmed Mazen Amin, Aya Aboutaleb, Ibrahim Gowaily, Youssef Soliman, Basel Abdelazeem
Guideline-directed medical therapy (GDMT) has improved outcomes in patients with heart failure, including the use of renin-angiotensin-aldosterone system inhibitors, which can hinder the excretion of potassium, resulting in hyperkalaemia. New potassium binders (NPBs) can prevent this adverse effect; however, the efficacy and safety of NPB for this indication have not been fully established. We conducted a systematic review and meta-analysis synthesizing randomized controlled trials (RCTs), which were retrieved by systematically searching PubMed, Web of Science, Scopus, and Cochrane through 26 April 2023...
November 27, 2023: ESC Heart Failure
#33
JOURNAL ARTICLE
Noriko Kuwae
The purpose of this report is to describe the efficacy of sacubitril/valsartan in 5 hemodialysis patients with hypertension, including a patient with heart failure with reduced ejection fraction (HFrEF) and a patient with preserved ejection fraction (HFpEF) focused on the functional changes in the heart. We switched from angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) to sacubitril/valsartan and compared blood pressure post dialysis, N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels and the findings of echocardiography for a period of 6 months...
November 23, 2023: CEN Case Reports
#34
JOURNAL ARTICLE
Ulrich Fischer-Rasokat, Matthias Renker, Efstratios I Charitos, Christopher Strunk, Julia Treiber, Andreas Rolf, Maren Weferling, Yeong-Hoon Choi, Christian W Hamm, Won-Keun Kim
AIMS: Cardiac decompensation (CD) in patients with aortic stenosis is a "red flag" for future adverse events. We classified patients undergoing transcatheter aortic valve implantation (TAVI) into those with acute, prior, or no prior CD at the timepoint of TAVI and compared their clinical presentation, prognosis, and effects of the prescribed medication during follow-up. METHODS: Retrospective analysis of patients of one center fulfilling the criteria of 30-day device success after transfemoral TAVI...
2023: Frontiers in Cardiovascular Medicine
#35
REVIEW
Tomasz Stompór, Agata Winiarska
Chronic kidney disease (CKD) and heart failure (HF) represent two modern diseases of civilization and are closely related. According to the concept of cardio-renal and reno-cardiac syndromes, most patients with CKD are affected by cardiovascular disease (CVD), and CVD (including HF) is one of the factors not only promoting progression of established CKD but also triggering its onset and development. Treatment of CVD and HF in CKD patients remains challenging since CKD patients are characterized by extremely diverse and strongly expressed risk profiles, and the data from well-designed clinical trials addressing this population are scarce...
2023: Kardiologia Polska
#36
REVIEW
Sohny Kotak, Warda Hassan, Marium Mehmood, Umesh Kumar, Fnu Sagreeka, Fnu Karishma, Pirya Kumari, Fnu Pirya, Javeria Saquib, Amna Iqbal, Anosh Aslam Khan, Giustino Varrassi, Mahima Khatri, Satesh Kumar
Acute myocardial infarction (MI) is one of the leading global healthcare emergencies, contributing to over three million global deaths. The purpose of this study is to investigate further the efficacy of sacubitril/valsartan over angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in reducing the risk of heart failure (HF) in post-MI patients and providing a clear evidence-based medicine guideline for future use. An electronic database search was conducted on English databases...
October 2023: Curēus
#37
JOURNAL ARTICLE
Daniela Tomasoni, Matteo Pagnesi, Giada Colombo, Mauro Chiarito, Davide Stolfo, Luca Baldetti, Carlo Mario Lombardi, Marianna Adamo, Giuseppe Maggi, Riccardo Maria Inciardi, Ferdinando Loiacono, Marta Maccallini, Alessandro Villaschi, Gaia Gasparini, Marco Montella, Stefano Contessi, Daniele Cocianni, Maria Perotto, Giuseppe Barone, Marco Merlo, Alberto Maria Cappelletti, Giuseppe Rosano, Gianfranco Sinagra, Daniela Pini, Gianluigi Savarese, Marco Metra
AIM: Persistent symptoms despite guideline-directed medical therapy (GDMT) and poor tolerance of GDMT are hallmarks of patients with advanced heart failure (HF) with reduced ejection fraction (HFrEF). However, real-world data on GDMT use, dose, and prognostic implications are lacking. METHODS AND RESULTS: We included 699 consecutive patients with HFrEF and at least one 'I NEED HELP' marker for advanced HF enrolled in a multicentre registry. Beta-blockers (BB) were administered to 574 (82%) patients, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or angiotensin receptor-neprilysin inhibitors (ACEi/ARB/ARNI) were administered to 381 (55%) patients and 416 (60%) received mineralocorticoid receptor antagonists (MRA)...
November 7, 2023: European Journal of Heart Failure
#38
JOURNAL ARTICLE
Yanhong Mou, Lijun Qin, Lili Wang, Yan Guo, Xiaowei Zhang, Jing Yu
OBJECTIVE: Heart failure with preserved ejection fraction (HFpEF) is a prevalent and clinically significant condition characterized by limited treatment options. In this context, the objective of this meta-analysis is to evaluate the effectiveness of sacubitril/valsartan compared to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in managing HFpEF. METHODS: A systematic search of relevant studies was conducted in PubMed, Embase, Web of Science, and Cochrane Library...
November 3, 2023: Alternative Therapies in Health and Medicine
#39
REVIEW
Snaiha I Narayan, Giselle V Terre, Rutvi Amin, Keshvi V Shanghavi, Gayathri Chandrashekar, Farhana Ghouse, Binish A Ahmad, Gowri N S, Christena Satram, Hamna A Majid, Danielle K Bayoro
Heart failure with reduced ejection fraction (HFrEF) is a clinical syndrome whose management has significantly evolved based on the pathophysiology and disease process. It is widely prevalent, has a relatively high mortality rate, and is comparatively more common in men than women. In HFrEF, the series of maladaptive processes that occur lead to an inability of the muscle of the left ventricle to pump blood efficiently and effectively, causing cardiac dysfunction. The neurohormonal and hemodynamic adaptations play a significant role in the advancement of the disease and are critical to guiding the treatment and management of HFrEF...
September 2023: Curēus
#40
REVIEW
Aurora Rist, Kaja Sevre, Kristian Wachtell, Richard B Devereux, Gerard P Aurigemma, Otto A Smiseth, Sverre E Kjeldsen, Stevo Julius, Bertram Pitt, Michel Burnier, Reinhold Kreutz, Suzanne Oparil, Giuseppe Mancia, Faiez Zannad
More than 90 % of patients developing heart failure (HF) have hypertension. The most frequent concomitant conditions are type-2 diabetes mellitus, obesity, atrial fibrillation, and coronary disease. HF outcome research focuses on decreasing mortality and preventing hospitalization for worsening HF syndrome. All drugs that decrease these HF endpoints lower blood pressure. Current drug treatments for HF are (i) angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or angiotensin receptor neprilysin inhibitors, (ii) selected beta-blockers, (iii) steroidal and non-steroidal mineralocorticoid receptor antagonists, and (iv) sodium-glucose cotransporter 2 inhibitors...
October 19, 2023: European Journal of Internal Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
